Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults
Back

Proof of Concept Treatment Study of Orally Administered VH4004280 or VH4011499 in HIV-1 Infected Adults

Completed

Open to: ALL

Age: 18.0 - 65.0

London

Medical Conditions

HIV Infections

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


The primary purpose of the study is to evaluate the antiviral activity of orally administered VH4004280 and VH4011499 monotherapy over 10 days in human immunodeficiency virus (HIV-1) infected Treatment-NaĂŻve (TN) participants.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Oct 2023 Jun 2024

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : VH4004280 was administered as tablets orally at Day 1.

Intervention Arm Group : Part 1a: VH4004280 Dose Level 1;Part 1a: VH4004280 Dose Level 2;Part 2a: VH4004280 pre-specified dose;

Intervention Type : DRUG
Intervention Description : VH4011499 was administered as tablets orally at Day 1 and Day 6.

Intervention Arm Group : Part 1b: VH4011499 Dose Level 1;Part 1b: VH4011499 Dose Level 2;Part 2b: VH4011499 pre-specified dose;

Intervention Type : DRUG
Intervention Description : VH4004280 Matching Placebo was administered as tablets orally at Day 1.

Intervention Arm Group : Matching placebo for VH4004280;

Intervention Type : DRUG
Intervention Description : VH4011499 Matching Placebo was administered as tablets orally at Day 1 and Day 6.

Intervention Arm Group : Part 1b: VH4011499 Dose Level 2;

Intervention Type : DRUG
Intervention Description : Antiretroviral therapy was administered as available and as per investigator's recommendation.

Intervention Arm Group : Matching placebo for VH4004280;Matching placebo for VH4011499;Part 1a: VH4004280 Dose Level 1;Part 1a: VH4004280 Dose Level 2;Part 1b: VH4011499 Dose Level 1;Part 1b: VH4011499 Dose Level 2;Part 2a: VH4004280 pre-specified dose;Part 2b: VH4011499 pre-specified dose;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • GSK Investigational Site
    London
    SE5 8RX


The study is sponsored by ViiV Healthcare



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT06039579
Last updated 09 September 2025

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top